EverSource Wealth Advisors’s Pacific Biosciences PACB Stock Holding History

EverSource Wealth Advisors’s Portfolio PACB Stock Details PACB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$5.35K	Buy	3,183 +398	+14%	+$579	﹤0.01%	3253
2026 Q1	$3.68K	Buy	+2,785	New	+$4.98K	﹤0.01%	3404
2025 Q2	–	Sell	-730	Closed	-$861	–	4330
2025 Q1	$861	Buy	730 +623	+582%	+$956	﹤0.01%	3283
2024 Q4	$196	Buy	+107	New	+$209	﹤0.01%	3435
2024 Q1	–	Sell	-465	Closed	-$4.56K	–	2962
2023 Q4	$4.56K	Buy	+465	New	+$3.8K	﹤0.01%	1897
2022 Q2	–	Sell	-113	Closed	-$1K	–	1844
2022 Q1	$1K	Hold	113	–	–	﹤0.01%	1658
2021 Q4	$2K	Buy	+113	New	+$2.73K	﹤0.01%	1594

Other funds holding PACB

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

EverSource Wealth Advisors's PACB Position: Q2 2026 in Review

EverSource Wealth Advisors increased its Pacific Biosciences (PACB) stake by 14% in Q2 2026, buying an estimated $579 and bringing the position to 3,183 shares worth $5.35K. The position accounts for ﹤0.01% of the portfolio, ranked #3253.

EverSource Wealth Advisors first reported a position in PACB in Q4 2021 and has held it in 7 quarters since. 223 funds tracked by Wall St. Rank hold PACB as of Q2 2026.

EverSource Wealth Advisors held 3,183 shares of Pacific Biosciences worth $5.35K as of Q2 2026.
EverSource Wealth Advisors bought 398 Pacific Biosciences shares in Q2 2026, an estimated $579.
Pacific Biosciences made up ﹤0.01% of EverSource Wealth Advisors's portfolio in Q2 2026, its #3253 holding.
EverSource Wealth Advisors first reported a position in Pacific Biosciences in Q4 2021 and has held it in 7 quarters since.
223 funds tracked by Wall St. Rank held Pacific Biosciences as of Q2 2026.

Based on EverSource Wealth Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.